LLY

901.38

-1.47%↓

JNJ

235.59

+0.03%↑

ABBV

204.74

-0.39%↓

NVS

148.66

+0.06%↑

AZN

185.11

+0.15%↑

LLY

901.38

-1.47%↓

JNJ

235.59

+0.03%↑

ABBV

204.74

-0.39%↓

NVS

148.66

+0.06%↑

AZN

185.11

+0.15%↑

LLY

901.38

-1.47%↓

JNJ

235.59

+0.03%↑

ABBV

204.74

-0.39%↓

NVS

148.66

+0.06%↑

AZN

185.11

+0.15%↑

LLY

901.38

-1.47%↓

JNJ

235.59

+0.03%↑

ABBV

204.74

-0.39%↓

NVS

148.66

+0.06%↑

AZN

185.11

+0.15%↑

LLY

901.38

-1.47%↓

JNJ

235.59

+0.03%↑

ABBV

204.74

-0.39%↓

NVS

148.66

+0.06%↑

AZN

185.11

+0.15%↑

Search

Quanterix Corp

Deschisă

SectorSănătate

3.74 -10.31

Rezumat

Modificarea prețului

24h

Curent

Minim

3.71

Maxim

4.2

Indicatori cheie

By Trading Economics

Venit

10M

-23M

Vânzări

3.7M

44M

Marjă de profit

-52.712

Angajați

450

EBITDA

15M

-17M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+75.23% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-75M

221M

Deschiderea anterioară

14.05

Închiderea anterioară

3.74

Sentimentul știrilor

By Acuity

35%

65%

101 / 350 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

75.23% sus

Prognoză pe 12 luni

Medie 7.5 USD  75.23%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

101 / 350 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat